​Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing innovative treatments for a broad range of fibrotic diseases. Founded in 2020 with support from HealthCap and Novo Seeds, Tribune's research builds upon the work of co-founder Dr. Ole J. Kaasbøll, who advanced studies on CCN protein signalling in Professor Håvard Attramadal's laboratory at Oslo University Hospital.

The company's lead candidate, TRX-44, is designed to mimic the function of CCN5, an endogenous protein that counteracts the pro-fibrotic effects of other CCN family members. By targeting these proteins, Tribune aims to develop disease-modifying therapies capable of halting or even reversing fibrosis across multiple organ systems.